Skip to main content
. Author manuscript; available in PMC: 2013 Aug 15.
Published in final edited form as: Cancer Res. 2012 Jun 27;72(16):4154–4164. doi: 10.1158/0008-5472.CAN-11-2848

FIGURE 6. Activated β-catenin protects from combinatorial therapies.

FIGURE 6

A) HCC4006 cells were treated as in Figure 3A and 4C with the indicated drugs for 48 or 72 hours, and then analyzed by western blotting for AXIN-1 or Lamin-A. B) HCC4006 cells were treated with gefinitib plus XAV939 as in A for the indicated times, and blotted for AXIN-1, activated β-catenin or Actin. C) HCC4006 cells expressing vector or activated β-catenin were treated as in A with the indicated drugs for 4 days and replated for 3 days without drugs. Viable cell counts were graphed, normalized to DMSO treatment. D) HCC4006 cells expressing vector or activated β-catenin were treated in sextuplicate with DMSO, gefitinib and/or pyrvinium as indicated for 5 days, and cell viability assessed by MTT assays. * indicates p<0.05, ** p<0.01, and *** p<0.001.